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ABSTRACT 
Wahid, F.N., Behnke, J.M. and Conway, D.J., 1989. Factors affecting the efficacy of ivermectin 
against Heligmosomoides polygyrus (Nematospiroides dubius ) in mice. Vet. Parasitol., 32: 325- 
340. 
The efficacy of ivermectin against Heligmosomoides polygyrus was investigated in 5 mouse 
strains (CFLP, NIH, C57Bllo, BALB/c  and CBA ) using a variety of dose levels, and subcutaneous 
and oral administration, Heligmosomoides polygyrus were not completely eliminated when 5 mg 
kg 1 of ivermectin was given 6 days after infection, but 10 mg kg- ~ was totally effective. Signifi- 
cant mouse-strain variation in drug efficacy was detected, NIH mice requiring treatment with 
higher doses than CFLP mice in order to bring about a comparable level of larvicidal activity. 
Ivermectin was more effective when given subcutaneously than when given orally, regardless of 
the dose administered or the strain of mouse tested. The anthelmintic effect of the treatment was 
more persistent in CFLP mice given 20 mg kg-~ subcutaneously than in NIH mice or in mice 
treated orally, and a 20-day interval between administration and infection was insufficient o 
prevent inhibition of parasite survival. Ivermectin was shown to be totally effective at 20 mg kg- 1 
given subcutaneously in killing immune arrested larvae of H. polygyrus. 
INTRODUCTION 
The murine trichostrongyle Heligmosomoides polygyrus (Nematospiroides 
dubius) has been used extensively as a laboratory model of chronic gastro- 
intestinal nematode infection because in most available mouse strains primary 
infections last 8-10 months (Ehrenford, 1954; Williams and Behnke, 1983; 
Keymer and Hiorns, 1986). The parasite has been exploited by pharmaceutical 
firms in anthelmintic s reens for many years because it is easy and inexpensive 
to maintain and has a life cycle which is very similar to that of parasites with 
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medical and veterinary importance. The adult stages of H. polygyrus can be 
readily removed from the mouse intestine by a single treatment with pyrantel, 
an anthelmintic which has been widely employed to abbreviate infections for 
experimental purposes (Behnke and Wakelin, 1977; Jacobson et al., 1982). 
The tissue stages of H. polygyrus (1-8 days post infection) are hardly affected 
by pyrantel and the drug cannot be used to terminate infections earlier than 
10-14 days post infection (Behnke and Wakelin, 1977; Behnke and Robinson, 
1985 ). Nevertheless, there is evidence that the earlier stages are immunogenic, 
particularly L4 and hence there is a requirement for drugs that show high ef- 
ficacy against the tissue-dwelling larval stages ofH. polygyrus (Jacobson et al., 
1982; Cayzer and Dobson, 1983; Pritchard et al., 1984) in order to allow ex- 
perimental manipulation during this phase of infection. 
Ivermectin, the 22, 23 dihydro derivative of avermectin B1, an important 
anti-parasitic agent derived from naturally occurring fermentation products, 
exhibits a broad spectrum of activity at extremely low dosages against a wide 
variety of nematode and arthropod parasites of livestock (Campbell and Benz, 
1984; Campbell, 1985). Ivermectin is also effective against H. polygyrus and 
we have used the drug at a variety of dose levels to abbreviate infections de- 
veloping through the immunogenic L 4stage. During the course of these xper- 
iments we became aware that ivermectin was not totally effective in eradicat- 
ing larval parasites at the doses reported previously to be completely arvicidal 
(5 mg kg-1 orally; Sayles and Jacobson, 1983). This prompted a reinvestiga- 
tion of the drug doses and other variables influencing efficacy against H. 
polygyrus and our findings are presented in this paper. 
MATERIALS AND METHODS 
Animals 
Random-bred male and female CFLP and syngeneic NIH, BALB/c, C57Bllo 
and CBA mice were bred and maintained under conventional nimal-house 
conditions in the Zoology Department of Nottingham University. The mice 
were used when about 6-8 weeks old. 
Parasite 
The strain of H. polygyrus used in this work was obtained in 1975 from the 
Wellcome Research Laboratories (Beckenham, Kent) and has been main- 
tained since, in outbred CFLP mice. The maintenance of the parasite and the 
methods used for infection and recovery have already been described (Behnke 
and Wakelin, 1977; Jenkins and Behnke, 1977 ). In order to assess drug efficacy 
against arrested larvae, NIH mice were immunized by a divided primary infec- 
tion schedule with 120 larvae being given on Days 0, 2, 4, 7, 9 and 12. The mice 
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were then treated with pyrantel (Strongid-P paste, Pfizer) on Days 15, 21, 28 
and 35. The challenge infection was administered on Day 56. Further details 
of this immunization procedure were reported by Behnke and Wakelin ( 1977 ). 
Faecal egg counts 
One gram of faeces was taken from the pooled faeces of all the mice in each 
group, deposited over the preceding 24 h, and was dispersed in 10 ml of 50% 
saturated saline. This suspension was washed through a sieve (aperture size, 
800/~m) with 35% zinc sulphate solution and the eggs were counted after flo- 
tation in standard McMaster counting slides, as described by Gordon and 
Whitlock (1939). The counts were expressed as the number of eggs g-1 of 
whole faeces. 
Anthelmintic treatment 
Ivermectin was available as a commercial preparation, Ivomec which con- 
tains 1% w/v of the anthelmintic (MSD AGVET). The required concentra- 
tions of ivermectin were obtained by appropriate dilution of this preparation 
with sterile distilled water. The resulting fine suspension was injected in vol- 
umes 0.1-0.3 ml within minutes of preparation. 
Pyrantel embonate (Strongid-P paste, Pfizer) was administered orally to 
some mice in Experiment 12 at a dose of 100 mg kg -1, which is known to be 
adequate for removing all adult worms from the intestinal lumen (Behnke and 
Wakelin, 1977). 
Cortisone 
Cortisone acetate (Cortistab, Boots) was given by subcutaneous injection 
every second day from Day 10 after challenge infection in Experiment 12. The 
first two injections were at 2.5 mg/mouse and the remainder at 1.25 mg/mouse. 
All the control and treated mice in Experiment 12 were given oxytetracycline 
hydrochloride (Terramycin, Pfizer) in their drinking water at a concentration 
of 3 g 1-1 (Behnke and Parish, 1979). 
Analysis of results 
All the results are presented as the mean number of worms recovered (MWR) 
_+ SEM and the percentage reduction in mean worm recovery was calculated 
in relation to the combined MWR of non-treated and saline or water-treated 
control groups within a particular experiment. The data were analysed for sig- 
nificance using a nonparametric Mann-Whitney U-test and a value o fP  < 0.05 
was considered to be significant (Siegel, 1956). 
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RESULTS 
Dose response 
Several experiments were carried out in which the dose of ivermectin used 
was varied. Table 1 presents the results of one such experiment in female NIH 
mice. Ivermectin was administered orally at 7 dose levels, 6 days following 
infection with 250 larvae. 
At 10 and 20 mg kg- 1, ivermectin prevented all the parasites from surviving 
until autopsy. At these dose levels we could not detect any adverse ffect of the 
drug on our mice. Ivermectin, at 5 mg kg-1, did not clear the entire worm 
burden, although the MWR was reduced by 98.2%. Lower doses were propor- 
tionally less effective and at 0.3125 mg kg-1 (6.1% reduction ) the drug failed 
to affect parasite survival. This experiment was repeated using the same strain 
of mice and covering comparable dose levels of ivermectin. The results were 
almost identical. At 5.63 mg kg -1 the MWR on Day 21 was reduced by 98.7%. 
At 0.35 mg kg-1 the worm burden was reduced by only 15.7%. 
Comparison of oral and subcutaneous routes of administration ofivermectin 
Ivermectin is known to be effective against nematode parasites whether given 
orally or subcutaneously. In Experiment 2, four dose levels were compared in 
TABLE1 
Experiment 1. The effect of varying the dose of ivermectin administered orally 
Dose 1 Group 2 No. mice Mean worm recovery ± SEM Reduction ~
(%) 
20.0 A 3 0 i00 
I0.0 B 3 0 I00 
5.0 C 5 3.8 ± 2.0 98.2 
2.5 D 6 45.8 ± 6.3 78.7 
1.25 E 6 72.3 ± 15.7 66.4 
0.625 F 5 179.2 ± 2.0 16.0 
0.3125 G 5 202.4_+ 4.3 6.1 
None  H 6 207.5 ± 4.6 
Saline I 6 222.5 ± 6.3 
~Ivermectin was administered orally on Day 6 of infection at the dose shown in mg kg- i. 
~The mice used were all female NIH and were killed on Day 21 of infection for worm counts. 
3The percentage r duction in worm recovery was calculated in relation to the mean worm recovery 
from Groups H and I combined (215.0 ± 4.1 ). Groups H and I did not differ significantly. 
Statistical analysis of results: Groups A, B, C, D, E and F were all significantly different from 
Groups H and I, combined (P  < 0.001 ); Group G was not significantly lower. 
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TABLE2 
Experiment 2. Comparison of the efficacy of ivermectin after oral or subcutaneous administration 
on Day 6 post-infection 
Dose~ Mean worm recovery +_ SEM 2 (% reduction ) P 
Oral treatment Subcutaneous treatment 
5.0 45.6 +- 13.3 34.2 +- 11.3 0.155 
(77.6) (83.2) 
2.5 69.5___ 6.6 114.2"-_ 9.1 0.04 
(65.9) (43.9) 
1.25 110.0 _ 10.5 164.8 +- 5.5 0.02 
(46.0) (19.1) 
0.3125 191.8--, 4.8 198.0_+ 5.5 0.12 
(5.8) (2.8) 
Water 204.2+- 4.4 197.8+- 2.5 NS 
None 209.0"-- 8.1 
1The dose of ivermectin is given in g kg-1. All the mice were infected with 250 L~ of H. polygyrus, 
treated with ivermectin or sterile water on Day 6 and were killed for worm counts on Day 21 post- 
infection. 
2All groups comprised 6 female NIH mice. The percentage reduction in MWR was calculated in 
relation to the MWR from the mice receiving sterile water and no treatment. These groups did 
not differ significantly from one another. The overall MWR from the combined control groups 
was 203.7+3.2 (n=17) .  
groups of 6 NIH mice treated either orally or subcutaneously. Again the ani- 
mals were infected with 250 larvae and were dosed on Day 6. 
The results are presented in Table 2 and it can be seen that no dose was 
completely effective in eradicating the parasites, although three of the doses 
reduced the MWR significantly. At intermediate dose levels 1.25-2.5 mg kg-1, 
the orally dosed mice showed better protection than those treated subcutane- 
ously but at higher doses the reverse was true. Other experiments reported in 
this paper show greater and more consistent reductions in worm burden fol- 
lowing subcutaneous treatment (see Tables 4 and 5). 
The efficacy of ivermectin given at different times during infection 
It was important o establish whether ivermectin would be equally effica- 
cious when given on different days following infection with H. polygyrus. NIH 
mice were therefore treated orally with ivermectin, on alternate days following 
the larval inoculum and at 2 dose levels which were calculated to give high but 
not complete protection. The results of Experiment 3 are presented in Fig. 1. 
The data show that on Day 6 ivermectin was less effective compared with ear- 
lier or later stages of infection. At 5 mg kg-1, 82.4% of the worms were cleared 
when ivermectin was given on Day 6, compared with 96.8% on Day 2 or 95.1% 
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Fig. 1. Exper iment  3. The effect of ivermectin given at 2.5 and 5.0 mg kg-  1 at different times 
during infection. Groups of 5 female NIH mice were treated with 2.5 (O)  or 5.0 (• )  mg kg-  ' 
ivermectin on the days shown. All the mice were infected with 250 larvae and were killed for worm 
counts on Day 21. The results are expressed in terms of percentage reduction in worm recovery in 
relation to the combined worm burden (180.0_+2.2, n=10)  of a non-treated control group 
( 181.2 _+ 2.9, n -- 5 ) and a control group treated with sterile water ( 178.8 _+ 3.4, n -- 5 ). Statistical 
analysis of results: the points with the same superscript were compared and have the following P 
values: 1, P=0.08;  2, P=0.08;  3, P - -0 .56  (NS) ;  4, P=0.08;  5, P=0.04;  6, P=0.111 (NS) ;  7, 
P=0.04;  8, P=0.155 (NS) .  
on Day 10. A dose of 2.5 mg kg -1 administered on Day 6, resulted in 70.9% 
protection whereas treatment on Day 2 gave 82.1%. 
This experiment was repeated using CFLP mice (Experiment 4; 5 female 
mice per group) and again 2 dose levels were employed. Mice were treated 
orally on Days 1, 3, 5, 7 and 9. Although some variation in MWR was obtained, 
there was no indication that the efficacy of ivermectin varied with time of 
injection. Thus, when mice were treated at 5 mg kg- 1, the percentage reduction 
in MWR ranged from 99.2% (Day 7) to 100% (Days 7 and 9). At 2.5 mg kg -1 
the worm burdens were reduced from 97.0% (Day 3) to 99.0% (Day 7). It was 
also apparent that both doses were considerably more effective in CFLP mice 
(Experiment 4) than in NIH mice (Experiment 3). 
The effect of host strain and sex 
Experiments 3 and 4 suggested that ivermectin was not equally effective in 
different mouse strains. Male mice of 4 different syngeneic strains were there- 
fore compared and female mice of two of the strains were also investigated. 
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TABLE 3 
Experiment 5. Comparison of the efficacy of oral treatment with ivermectin at 2 dose levels in 4 
strains of mice 
Group of mice I Mean worm recovery ±SEM 2 (% reduction ) 
Strain Sex No treatment 2.5 mg kg -1 ~* 10 mg kg- 
BALB/c Male 149.5 ± 5.7 24.0 ± 7.1 0.8 ± 0.4 
(83.9)4 (99.5) 
BALB/c Female 133.7 ± 3.8 4.0 ± 1.8 0 
(97.0) 4 (100) 
C~TBllo Male 142.7 ± 4.2 10.8 ± 2.9 0 
(92.4) ~'6'7 (100) 
C.~7Bllo Female 143.3 ± 5.0 12.1 ± 3.0 0 
(91.5) '~ (100) 
NIH Male 145.3 ± 4.1 38.9 ± 4.8 7.6 ± 3.2 
(73.3) 6's (94.8) 
CBA Male 152.2 ± 6.4 33.2 ± 5.6 0 
(78.2) 7's (100) 
~All the mice were infected with 200 H. polygyrus L3 and were killed on Day 21 post-infection. 
2The percentage r duction in MWR was calculated by comparison with the control (non-treated) 
group of the same strain and sex. 
~3Ivermectin was administered orally on Day 6 post-infection at the doses hown in mg kg- 1. 
Statistical analysis of results. The worm burdens in groups with the same superscript no. were 
compared and have the following P values: 4and 5, P = 0.15; 6 and 7, P = 0.01; 8, P= 0.7. 
Ivermectin was given orally at 2 dose levels on Day 6 following infection with 
200 larvae. The results of Exper iment  5 are shown in Table 3. 
The worms in male N IH  mice were least affected by ivermectin at both dose 
levels. Worms in CBA mice were also poorly affected in comparison with those 
in C~TBllo mice. The sex of the host had no influence on the efficacy of iver- 
mectin in C57B110 and BALB/c ,  although in the latter strain female mice had 
lower worms burdens than males, but the difference was not statistically 
significant. 
The relationship between efficacy of ivermectin and mouse body weight 
It was evident from Exper iment  5 that  when ivermectin was given at a par- 
ticular dose level to mice of different strains, the drug's efficacy in removing 
worms was not identical. The results from Exper iments 3 and 4 implied that  
N IH  mice would have to be given a higher dose of ivermectin than CFLP  mice 
in order to achieve the same level of protection. CFLP  mice are significantly 
heavier than N IH  mice (40-60 g compared with 20-30 g for N IH) .  It was pos- 
sible therefore that  the main factor determining drug efficacy was host weight, 
possibly determined by fat content,  as the drug is highly lipophilic. An exper- 
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iment was devised to explore the relationship between drug efficacy and host 
weight using NIH and CFLP mice. Male mice of both strains were allocated to 
5 groups. Two groups of each strains were given ivermectin at 2.5 mg kg-1 
orally or subcutaneously and it is clear from Table 4 that this dose level was 
again considerably more effective in CFLP than in NIH mice irrespective of 
the route of administration. Two further groups of mice of each strain were 
given a uniform dose of ivermectin calculated from the mean weight of the 
heterologous mouse strain to be required in order to give the latter strain a 
dose of 2.5 mg kg-1. Thus the NIH mice in Groups D and E received almost 
double the dose given to Groups B and C, whereas the CFLP mice in Groups I
and J received almost half the dose given to Groups G and H. Despite these 
adjustments for body weight of the heterologous strain, ivermectin was still 
more effective in CFLP than in NIH mice. Even at the overall ower dose given 
to mice in Groups I and J the percentage protection was greater than in NIH 
mice in Groups D and E, given the highest dose (97.1 vs. 89.6, 99.8 vs. 96.4). 
It is also apparent hat subcutaneous administration of ivermectin was more 
effective than the oral route. 
TABLE 4 
Experiment 6. The relationship between the efficacy of ivermectin and mouse body weight 
Group Strain 1 Treatment Mean worm recovery _+ SEM Reduction 
(%) 
Dose Route 
A NIH None 160.1 _+ 5.3 
B NIH 2.5 Oral 43.2 + 2.8 734s 
C NIH 2.5 SC 4 22.4 _+ 2.9 86 ~'~ 
D NIH 4.52 Oral 16.6 _+ 3.7 89.6 ~'~ j  
E NIH 4.52 SC 5.7_+ 2.0 96.47'11 
F CFLP None 155.7_+ 5.1 
G CFLP 2.5 Oral 3.6 _+ 1.5 97.74~' 
H CFLP 2.5 SC 0 100 ~'7 
I CFLP 1.4 :~ Oral 4.8 _+ 1.9 97.1 ~'l° 
J CFLP 1.4 :~ SC 0.3 _+ 0.3 99.89'1~ 
1All groups comprised 7male mice infected with 250 larvae, treated with ivermectin on Day 6 and 
killed for worm counts on Day 21. 
eThe dose of ivermectin given to Groups D and E was calculated using the mean body weight of 
mice in Groups G and H and the dose if given to the CFLP mice in Groups G and H would have 
resulted in a mean dose of 2.5 mg kg- 1. 
:~The dose of ivermectin given to Groups I and J was calculated using the mean body weight of 
mice in Groups B and C and if given to the NIH mice in Groups B and C would have resulted in 
a mean dose of 2.5 mg kg 1. Statistical analysis of results. Groups with the same superscript were 
compared and have the following P values: 4, 6, 7, 8 and 9, P--0.001; 5, P=0.02;  11, P=0.01;  10, 
P = 0.05. 
4SC, subcutaneous. 
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The effect of intensity of infection on the efficacy of ivermectin 
Groups of 6 female CFLP mice were infected with either 50, 100 or 250 larvae 
of H. polygyrus. Ivermectin was given at 2.5 mg kg-1 or 10 mg kg-1, orally or 
subcutaneously on Day 6 following infection. In total, the experiment com- 
prised 15 groups of mice. At 10 mg kg-  1 all the parasites were killed irrespective 
of the infection intensity or route of drug administration. At 2.5 mg kg -1 the 
percentage reduction in MWR relative to the control untreated group at the 
same infection intensity ranged from 92.7% (orally treated mice infected with 
50 larvae) to 100% (subcutaneously treated mice infected with 50 larvae). No 
significant relationship was observed between infection intensity and drug 
efficacy. 
Persistence of the anthelmintic effect following treatment with ivermectin 
Five experiments were carried out, in which we investigated the duration of 
the anthelmintic effect following treatment of mice with ivermectin. The drug 
was administered at 2.5 or 20 mg kg- 1 either orally or subcutaneously to CFLP 
and NIH mice, on various days up to 3 weeks before infection. The results are 
summarised in Table 5. Orally administered ivermectin did not persist long. 
The only significant difference observed was in Experiment 8 where treatment 
at 20 mg kg-1, 2 days before infection, gave a significant reduction in parasite 
burden. Subcutaneously administered ivermectin was more persistent partic- 
ularly at 20 mg kg-1 in CFLP mice, worm burdens being reduced when mice 
were treated up to 20 days before infection. NIH mice treated subcutaneously 
with 20 mg kg- 1 showed residual activity for 7-14 days. 
Experiment 11 (Table 6) compared the residual activity of ivermectin, 1 
week following treatment at 5 dose levels and by both oral and subcutaneous 
routes in CFLP mice. Oral treatment at 20 mg kg- 1 resulted in 22.6% reduction 
in worm burden, but the lower dose levels did not significantly affect parasite 
survival. Administration of the drug subcutaneously, however, resulted in 
marked activity at 10 and 20 mg kg -1, and a weak effect at 5 mg kg -1, but no 
significant effect at the lowest dose level. 
The effect of ivermectin on immune-arrested larvae 
When a challenge inoculum is administered to NIH mice which have been 
made immune by the divided immunizing regime, the majority of larvae fail to 
develop and become arrested in development. These arrested larvae will begin 
to develop when mice are treated with the immunosuppressive drug cortisone 
(Behnke and Parish, 1979). This model can be used to determine whether a 
particular anthelmintic has efficacy against larval stages of H. polygyrus 
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TABLE 6 
Experiment 11. Persistence of ivermectin in CFLP mice given a range of doses 1 week before 
infection 
Dose 1 Mean worm recovery _+ SEM 2 ( % reduction ) 
Oral treatment Subcutaneous treatment 
Water 158.0+_ 8.7 
20 122.3+_ 8.9 3.6_+ 3.63 
(22.6) (97.7) 
10 144.0 _+ 14.7 63.2 _+ 16.14 
(8.0) (60.0) 
5 146.6_+ 5.9 116.8_+ 9.25 
(7.6) (26.1) 
2.5 152.8_+ 7.1 146.4+11.8 
(3.3) (7.3) 
1.25 129.3_+ 8.4 164.8_+ 8.4 
(18.2) (0) 
lIvermectin was administered 7 days prior to infection. The doses given are shown in mg kg- 1. 
2All groups comprised 5 female CFLP mice infected with 250 larvae and killed on Day 21 for worm 
counts. 
Statistical analysis of results. All the groups were compared with the group treated with water and 
those with a superscript no. have the following P values: 3 and 4, P=0.02; 5, P=0.9.  All the 
remaining roups had higher values for P. 
TABLE 7 
Experiment 12. The effect of ivermectin on immune arrested larvae 
Group Treatment Mean worm 
recovery _+ SEM 
Immunizing Challenge Anthelmintic 3 Cortisone 4 
infection 1 infection 2 Day 10 Day 10 + Day 10 Day 26 
A - + - - 70.0_+3.6 94.0_+4.1 
B - + Pyrantel - Nd 5 15.9 _+ 1.4 
C - + Ivermectin Nd 0 
D + + - - 2.3_+1.5 2.2+_0.6 
E + + - + Nd 42.5 -+ 4.8 
F + + Pyrantel + Nd 43.5 _+ 4.5 
G + + Ivermectin + Nd 0 
1Groups of female NIH mice were immunized by the divided primary infection. 
2All the groups were challenged on Day 0 with 100 larvae and were killed for worm counts 10 or 
26 days after infection. 
3Pyrantel was given orally at 100 mg kg-1. Ivermectin was administered subcutaneously at 20 mg 
kg- 1. 
4Cortisone was administered very 2 days from Day 10 onwards. 
'~Nd-- not done. 
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Fig. 2. Experiment 12. The effect of ivermectin on immune arrested larvae of/-/, polygyrus. Faecal 
egg counts were carried out on the 5 groups in this experiment. See Table 7 for full explanation: 
Group A, O; Group D, I ;  Group E, [~; Group F, ~; Group G, O. 
arrested in the intestinal tissues. Table 7 presents the results of one such ex- 
periment and Fig. 2 summarises the faecal egg counts which were monitored 
throughout the challenge infection. 
As can be seen from Table 7, pyrantel had a significant effect against he 
adult stages of the parasite when administered 10 days after infection, but 
some worms survived (Group B), presumably larvae which had not yet re- 
turned to the gut lumen. Ivermectin completely cleared all adult worms and 
any persisting larvae (Group C). Mice which had been immunized were re- 
sistant o infection and very few worms were recovered by incubation on Days 
10 and 26 (Groups D and A). However, these mice contained larvae which 
failed to emerge on incubation because when cortisone was administered from 
Day 10 onwards the worm burden on Day 26 was 42.5 + 4.8 (Group E). Figure 
2 shows that the worms in mice in Group E began to produce eggs within 5 
days of cortisone treatment, confirming that development was triggered by 
cortisone. No eggs were observed in the faeces of the mice from Group D. 
When immune-challenged mice were treated with pyrantel on Day 10 and 
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subsequently with cortisone, adult worms developed. Egg output in Group F, 
was indistinguishable from that in Group E and comparable worm burdens 
were recovered on Day 26. Pyrantel was therefore ineffective against he ar- 
rested larvae in immune mice 10 days after challenge infection. In contrast, 
ivermectin was 100% effective. No eggs were observed in the faeces of mice 
from Group G and no worms were recovered on Day 26 post challenge, even 
though cortisone treatment was maintained from Day 10 to Day 26. 
DISCUSSION 
Ivermectin (Ivomec) is an anthelmintic drug, with relatively wide spectrum 
activity against avariety of parasitic organisms. It is a member of the parent 
family of chemicals, the avermectins, originally discovered as having anthel- 
mintic properties in a screen involving H. polygyrus (Campbell et al., 1984). 
Despite this, information on the effects of ivermectin on H. polygyrus in vivo, 
is not readily available to support he design of experiments exploiting the 
drug's potent larvicidal effects, in manipulating the course of infection for im- 
munological nalyses of the host-parasite r lationship. The study reported in 
this paper was necessary toprovide us with data on optimal doses of ivermec- 
tin. The adult stages of H. polygyrus are immunosuppressive n the mouse 
(Behnke, 1987 ) whilst the larval stages provide the antigenic stimulus, which 
in responder strains results in the development of acquired immunity (Jacob- 
son et al., 1982; Behnke and Robinson, 1985). The larvae of H. polygyrus de- 
velop for 8-10 days in the muscularis externa nd undergo amoult during this 
period. In order to identify the larval stages which provide the immunogenic 
signal in mice it was necessary tobe confident that the anthelmintic drug used 
to abbreviate primary infections was 100% effective; even a single worm es- 
caping the effects of treatment would complicate the interpretation of such 
experiments. Our results are in broad agreement with those published earlier 
by Sayles and Jacobson (1983) but differ significantly from those obtained by 
Rajasekariah etal. (1986). 
It is apparent from the results we have presented, that the dose of ivermectin 
reported by Sayles and Jacobson { 1983) to be totally effective in killing L4 
stages of H. polygyrus, 6days following infection, was not completely effective 
in our system. Although 5mg kg- 1 gave over 95% reduction i  parasite burdens 
in CFLP mice, NIH mice, treated at this dose level by subcutaneous injection, 
were less effectively cleared of worms (range, 82.4% reduction in Experiment 
3 to 98.2% in Experiment 1). A dose of 5 mg kg -1, considered by Sayles and 
Jacobson (1983) to be totally effective, was therefore an inappropriate dose to 
use in our system for achieving a complete clearance ofall parasites. The lowest 
dose at which we could be confident that the entire worm burden would be 
eradicated was 10 mg kg- 1 but a dose of 20 mg kg-1 would guarantee total 
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protection. At this dose we could not detect any harmful side effects on our 
mice. 
Overall our dose response data appear to show higher values necessary in 
order to achieve the drug efficacies reported by Sayles and Jacobson (1983), 
but these differences are marginal in comparison to the results reported by 
Rajasekariah et al. (1986). The latter authors found that 0.3 mg kg -1 was 
totally effective; over an order of magnitude difference in dose level. Rajase- 
kariah et al. (1986) used MAG mice in their study and it is possible that host 
strain differences influenced rug efficacy. Indeed we found that there were 
marked differences between mouse strains but we consider that the magnitude 
of the difference between our two sets of results to be too large to be explained 
solely in this way. 
In comparison with the optimal doses of ivermectin used in treating rumi- 
nants, dogs and man (0.1-0.3 mg kg-1; see reviews by Campbell and Benz, 
1984; Campbell, 1985), the doses required to ensure total eradication of H. 
polygyrus from mice were significantly higher. This may reflect relatively greater 
resistance to ivermectin by H. polygyrus, a possibility which is supported by 
the observation that in vitro cultured L4 stages of H. polygyrus responded to 
treatment with ivermectin in a distinctive way (Jenkins and Ibarra, 1984). 
The worms were not killed by relatively high doses of the drug although paral- 
ysis was induced at lower concentrations. It is also conceivable that physiolog- 
ical characteristics of the mouse necessitated higher dosage regimes in order 
to achieve toxic levels in the intestinal environment. In support, Ostlind et al. 
(1985) found that 2 mg kg-  1 of ivermectin were required to ensure total clear- 
ance of Syphacia obvelata from mice. 
The efficacy of ivermectin against H. polygyrus was markedly affected by the 
mouse strain. NIH mice required a significantly higher dose than comparably 
infected CFLP mice to achieve total clearance of worms and this difference 
was not solely explicable in terms of the total dose administered. CFLP mice, 
at almost twice the weight of NIH mice, received a higher total dose, based on 
a per kg body weight calculation. To compensate for this we gave NIH mice an 
identical total dose to that used in treating CFLP mice, but H. polygyrus were 
still not cleared as effectively as in the latter strain. Furthermore, we demon- 
strated that the anthelmintic effect of ivermectin was more persistent in CFLP 
than in NIH mice, especially when administered subcutaneously. This is con- 
sistent with observations made by McKellar and Marriner (1987) on tricho- 
strongyle infections in sheep and by Barth (1983) in cattle. The explanation 
for the persistence of ivermectin after subcutaneous administration may be 
slow drug release from the site of injection (Lo et al., 1985 ) leading eventually 
to higher and long-lasting plasma levels (Campbell, 1985; McKellar and Mar- 
riner, 1987). In our experiments, mice treated orally at 20 mg kg-1 did not 
show a residual effect for longer than 2-4 days. In contrast CFLP mice given 
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this dose subcutaneously, 20 days prior to infection developed lower worm bur- 
dens than controls. Moreover, this persistent effect was more marked in CFLP 
than in NIH mice, indicating again a degree of strain variation. These results 
have important implications for the design of experiments involving the 
administration of challenge infections after drug-abbreviated primary expo- 
sure. Oral dosing will not entail a long interval between drug administration 
and challenge, but subcutaneous application of ivermectin will require an in- 
terval of at least 3, and possibly 4-5, weeks to ensure that residual activity of 
the drug is totally abolished. The situation is further compounded by strain 
variation in drug efficacy and persistence and these aspects would have to be 
evaluated for each strain employed. 
The final aspect of ivermectin efficacy which we investigated was the drug's 
activity against arrested larvae. Experiment 12 exploited a system described 
earlier for inducing immune arrested evelopment of H. polygyrus in mice 
(Behnke and Parish, 1979 ). At 20 mg kg-1 ivermectin was totally effective in 
killing all arrested worms, whereas pyrantel failed to affect such larvae. This 
result is consistent with studies on arrested trichostrongyles in sheep (Mc- 
Kellar and Marriner, 1987), pigs (Murrell, 1981) and cattle (Barth and Pres- 
ton, 1987). 
In conclusion, our study was initiated because of the paucity of information 
on the optimum use of ivermectin in terminating larval infections with H. 
polygyrus. This report has provided pertinent information and moreover has 
identified aspects of the drug's effect which warrant further investigation. Our 
observations on mouse strain variation in efficacy and persistence have impli- 
cations for the use of ivermectin i different breeds of ruminants inagriculture. 
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